

Product Datasheet

TAZ/WWTR1 Antibody - BSA Free NB600-220

Unit Size: 0.1 mg

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 9

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NB600-220

Updated 9/9/2025 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NB600-220



NB600-220

TAZ/WWTR1 Antibody - BSA Free


Product Information	
Unit Size	0.1 mg
Concentration	1 mg/ml
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	PBS
Target Molecular Weight	44.1 kDa

Product Description	
Description	Novus Biologicals Rabbit TAZ/WWTR1 Antibody - BSA Free (NB600-220) is a polyclonal antibody validated for use in WB. Anti-TAZ/WWTR1 Antibody: Cited in 9 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Rabbit
Gene ID	25937
Gene Symbol	WWTR1
Species	Human, Mouse
Reactivity Notes	Human. Mouse reactivity reported in scientific literature (PMID: 28065575)
Specificity/Sensitivity	Reacts with residues 386-400, which is the PDZ-binding domain of the 49kDa human TAZ protein.
Immunogen	Synthetic peptide representing residues 386-400 of the human TAZ protein.


Product Application Details	
Applications	Western Blot
Recommended Dilutions	Western Blot 1:500 -1:1000
Application Notes	Western blot where a band is seen at ~49kDa. The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Images


Western Blot: TAZ/WWTR1 Antibody [NB600-220] - Pharmacologic targeting the Beta1-integrin-FAK-YAP1/TAZ signaling suppresses cancer spheroids and VASP is required for RhoA-mediated YAP1/TAZ dephosphorylation. Upper, 3D cancer spheroids were harvested for WB for CTGF. VASP knockdown reduced CTGF protein levels in KM12L4 and L3.6 cells. * $p < 0.05$ by t-test, $n = 3$ repeats. Lower, cells on Matrigel were treated with PF-228 ($3 \mu\text{M}$) and collected for WB. PF-228 reduced YAP1/TAZ protein levels. * $p < 0.05$ by t-test, $n = 3$ repeats. Samples derived from the same experiment and gels/blots were processed in parallel. Image collected and cropped by CiteAb from the following publication ([//www.nature.com/articles/s41698-017-0045-7](http://www.nature.com/articles/s41698-017-0045-7)) licensed under a CC-BY license.




Western Blot: TAZ/WWTR1 Antibody [NB600-220] - Western blot analysis of TAZ in MDCK cells using NB600-220 at 1:250 dilution.



Western Blot: TAZ/WWTR1 Antibody - BSA Free [NB600-220] - Pharmacologic targeting the β 1-integrin-FAK-YAP1/TAZ signaling suppresses cancer spheroids & VASP is required for RhoA-mediated YAP1/TAZ dephosphorylation. a Upper, 3D cancer spheroids were harvested for WB for CTGF. VASP knockdown reduced CTGF protein levels in KM12L4 & L3.6 cells. * $p < 0.05$ by t-test, $n = 3$ repeats. Lower, cells on Matrigel were treated with PF-228 (3 μ M) & collected for WB. PF-228 reduced YAP1/TAZ protein levels. * $p < 0.05$ by t-test, $n = 3$ repeats. Samples derived from the same experiment & gels/blots were processed in parallel. b, c PF-228 (3 μ M) or Verteporfin (5 μ M) reduced the size of L3.6 spheroids on Matrigel. * $p < 0.05$ by t-test; $n > 50$ per group. Bar: 100 μ m. d HCT116 cells expressing LacZ (control) or RhoAQ63L were seeded on Matrigel to induce cancer spheroids. Overexpression of RhoAQ63L increased the size of cancer spheroids. * $p < 0.05$ by t-test; $n > 50$ per group. e Control & VASP knockdown cancer spheroids were harvested for regular WB & Phos-tagTM gel-based WB. RhoAQ63L increased YAP1/TAZ protein levels & YAP1/TAZ dephosphorylation in control cells & these RhoAQ63L effects on YAP1/TAZ were abrogated by VASP knockdown. Densitometry data are shown on the right. * $p < 0.05$ by ANOVA, $n = 3$. f Control & VASP knockdown cancer spheroids were harvested for WB using anti-P-YAP (S127) & YAP1. RhoAQ63L reduced the ratio of P-YAP(S127) to YAP1 & this effect of RhoA on YAP1 dephosphorylation was partially reversed by VASP knockdown. * $p < 0.05$ by ANOVA, $n = 3$. Samples derived from the same experiment & gels/blots were processed in parallel. Error bar: S.D Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/29872721>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: TAZ/WWTR1 Antibody - BSA Free [NB600-220] - VASP knockdown suppresses the growth of 3D cancer spheroids by reducing P-FAK & YAP1/TAZ protein levels. a VASP knockdown in two human CRC cell lines significantly reduced the size of cancer spheroids. * $p < 0.05$ by t-test, $n > 50$ per group; Bar, 100 μ m. b VASP knockdown in two PDAC cancer cell lines significantly reduced the size of cancer spheroids. * $p < 0.05$ by t-test, $n > 50$ per group; Bar, 100 μ m. c Cancer spheroids were harvested for WB. VASP knockdown in 4 cell lines consistently reduced phosphorylation of FAK & Src & protein levels of YAP1/TAZ. The effect of VASP knockdown on phosphorylation of Akt or Erk was not consistent & it did not influence the total FAK & Src protein levels. Quantitative data of HCT116 are shown on the bottom. * $p < 0.05$, by t-test, $n = 3$. Samples derived from the same experiment & gels/blots were processed in parallel. Error bar: S.D Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/29872721>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Xiang X, Wang Y, Zhang H et al. Vasodilator-stimulated phosphoprotein promotes liver metastasis of gastrointestinal cancer by activating a beta 1-integrin-FAK-YAP1/TAZ signaling pathway 2018-01-22 [PMID: 29872721] (WB, Human)

Sero JE, Bakal C. Multiparametric Analysis of Cell Shape Demonstrates that b-PIX Directly Couples YAP Activation to Extracellular Matrix Adhesion Cell Syst 2017-01-25 [PMID: 28065575] (WB, Mouse)

Diepenbruck M, Waldmeier L, Ivanek R et al. Tead2 expression levels control Yap/Taz subcellular distribution, zyxin expression, and epithelial-mesenchymal transition. J. Cell. Sci. 2014-02-19 [PMID: 24554433] (WB, Mouse)

Suh JS, Lee JY, Choi YJ et al. Intracellular delivery of cell-penetrating peptide-transcriptional factor fusion protein and its role in selective osteogenesis. Int J Nanomedicine 2014-03-20 [PMID: 24648725] (WB, Human)

Details:

Purified recombinant TAZ fusion protein, Fig 1B. The specificity of the TAZ antibody was validated with recombinant TAZ protein by WB, Fig 1B.

Komar CM, Long MJ. Immunohistochemical techniques to identify and localize proteins of interest in paraffin embedded tissue sections. Methods Mol Biol. 2013-01-01 [PMID: 23100234]

Varelas X, Miller BW, Sopko R et al. The Hippo pathway regulates Wnt/beta-catenin signaling. Dev Cell. 2010-04-20 [PMID: 20412773] (WB, Human)

Chan SW, Lim CJ, Loo LS et al. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem. 2009-05-22 [PMID: 19324876] (WB)

Details:

WB (Fig 1A): Hs578T breast carcinoma cells. IF (Fig 5A): MCF10A breast carcinoma cells expressing recombinant TAZ. Notes: 1. The TAZ antibody is shown to recognize both TAZ (~50 kDa) and ~YAP (75 kDa) by WB (Fig 1A).2. The TAZ antibody showed the TAZ and

Yuen HF, McCrudden CM, Huang YH et al. TAZ expression as a prognostic indicator in colorectal cancer. PLoS One. 2013-01-01 [PMID: 23372686]

Chan SW, Lim CJ, Guo K et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 2008-04-15 [PMID: 18413727]

Details:

Fig 1A (Eleven human breast cancer cell lines) Fig 2B (MCF10A breast cancer cell line transduced with retrovirus expressing EGFP, TAZ, or Flag-TAZ, Hs578T and BT-549 breast cancer cells) Fig 3A (shRNA knockdown of TAZ in MCF-7 and Hs578T breast cancer cel



Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NB600-220

NBL1-16718	Tafazzin/TAZ Overexpression Lysate
NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NB600-220

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

